アスピリン感受性:冠動脈疾患の患者への影響
Raghava R Gollapudi1, Paul S Teirstein, Donald D Stevenson
1Divison of Cardiovascular Diseases, Scripps Clinic and the Scripps Research Institute, La Jolla, Calif 92037, USA.
JAMA
|December 23, 2004
まとめ
アセチルサリシル酸 (アスピリン) への過敏は一般的であり,しばしば呼吸道や皮膚の反応を引き起こします. 脱敏感化は多くの人にとって安全ですが,冠動脈疾患 (CAD) の患者についてはさらなる研究が必要です.
科学分野:
- 臨床免疫学 臨床免疫学について
- 薬理学 薬理学とは
- 心臓病学 心臓病学
背景:
- アセチルサリシル酸 (アスピリン) は慢性心血管疾患に広く使用されています.
- 少数の患者はアスピリンやその他のNSAIDに対して過敏を示します.
- アスピリン過敏症は,呼吸器系の問題やウルチカリアとして表れることがあります.
研究 の 目的:
- アスピリン過敏症の診断戦略を概説する.
- アスピリンに敏感な患者,特に冠動脈疾患 (CAD) の患者に対する治療ガイドラインを提供すること.
主な方法:
- MEDLINEとコクランデータベースの文献検索 (1966-2004).
- コントロールされた,英語で,ピアレビューされた研究の含有.
- 復元された記事からの参照のレビュー.
主要な成果:
- アスピリンにより悪化した呼吸器疾患は,人口の約10%に影響し,アスピリン誘発性ウルチカリアは0.07-0.2%に影響する.
- 感受性は主にサイクロオキシゲネーゼ-1阻害によるもので,まれにIgE媒介性である.
- ほとんどの患者は,慢性イディオパシー性ウルチカリアを患っている患者を除いて,アスピリンの無感化に成功することができます.
結論:
- アスピリンの過敏性は一般的であり,無感化はしばしば安全で効果的です.
- 現在限られたデータがあるため,CAD患者におけるアスピリン無感化の安全性と有効性を確認するために,さらなる大規模な試験が不可欠です.
関連する概念動画
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
01:26Acute Coronary Syndrome V: Nursing Management
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...